Intera achieva nova dual 1.5t

We performed noncontrast MRA using a 1.5T MR system (Intera Achieva Nova Dual 1.5T; Philips Healthcare) and a 16-channel phased-array body multicoil (SENSE XL Torso, Philips Healthcare). Next, MRA images were obtained using a respiratory-triggered two-dimensional single-shot b-TFE sequence (Balanced TFE M2D, Healthcare) in the transaxial (TR/TE, 2.8/1.39 ms; flip angle, 80°; matrix, 192 × 256; field of view, 40 × 26 cm; slice thickness/overlap, 6/2 mm; and acquisition time, 5 minutes), coronal (TR/TE, 2.9/1.43 ms; flip angle, 80°; matrix, 192 × 256; field of view, 40 × 36 cm; slice thickness/overlap, 7/3 mm; and acquisition time, 4 minutes), and sagittal (TR/TE, 2.6/1.31 ms; flip angle, 80°; matrix, 192 × 256; field of view, 40 × 36 cm; slice thickness/overlap, 7/3 mm; and acquisition time, 3 minutes) planes. Notably, we used the same transaxial plane parameters in both phantom and clinical studies.

Our Institutional Review Board approved this retrospective study, and the requirements for informed consent were waived.
For this retrospective study, we used electronic medical records including pharmacy records, imaging data and laboratory data. Between December 2015 and November 2017, referring to the medical data record, we enrolled 18 consecutive patients with HCV infection who achieved SVR by DAA therapy and underwent gadoxetic acid-enhanced MRI before and after therapy. In this study, we included the patients who underwent MRI using 3T MRI scanner (Achieva TX, 3T; Philips Healthcare, Best, The Netherlands) both before and after therapy. Seven patients were excluded because they underwent MRI examination using 1.5T MRI scanner (Intera Achieva Nova Dual, 1.5T, Philips Healthcare) scanner before and/or after therapy. A final total of 11 patients were enrolled in this study, and their characteristics are summarized in Table 1. Antiviral therapy and treatment duration (12 or 24 weeks) was indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the current international guidelines.^{7 (link)} SVR was defined as HCV ribonucleic acid results below the lower limit of quantification at a timepoint 24 weeks or more after the end of treatment.^{7 (link)}